Faster global financial news!
Exelixis
-
Exelixis (EXEL) stock dropped after FDA delayed potential approval of its new colon cancer treatment by three months
Exelixis (EXEL) stock dropped out of a buy zone Friday after the Food and Drug Administration delayed the potential approval of its new colon cancer treatment by three months. The combination includes
-
IBD: Exelixis (EXEL) Stock Breaks Out After Earnings Resistance, Up 0.08% Intraday to $59.08
IBD notes that Exelixis stock broke out past a 57.57 USD flat-base buy point, with the buy range extending up to 60.45 USD. The stock holds an IBD Composite Rating of 99/99 and an industry group rank
-
Exelixis (EXEL), a cancer treatment company, saw its stock price hit a new all-time high on Wednesday, as the market focused on a key FDA action.
Exelixis (EXEL), a cancer treatment company, saw its stock price hit a new all-time high on Wednesday, as the market focused on a key FDA action.
-
Exelixis (EXEL) stock fell early Thursday after the biotechnology company reported mixed second-quarter earnings, with sales of its core cancer drug cabozantinib missing expectations.
The company's cancer drug Cabometyx had quarterly sales of $570.6 million.
-
Exelixis (EXEL) stock dropped after FDA delayed potential approval of its new colon cancer treatment by three months
Exelixis (EXEL) stock dropped out of a buy zone Friday after the Food and Drug Administration delayed the potential approval of its new colon cancer treatment by three months. The combination includes
-
IBD: Exelixis (EXEL) Stock Breaks Out After Earnings Resistance, Up 0.08% Intraday to $59.08
IBD notes that Exelixis stock broke out past a 57.57 USD flat-base buy point, with the buy range extending up to 60.45 USD. The stock holds an IBD Composite Rating of 99/99 and an industry group rank
-
Exelixis (EXEL), a cancer treatment company, saw its stock price hit a new all-time high on Wednesday, as the market focused on a key FDA action.
Exelixis (EXEL), a cancer treatment company, saw its stock price hit a new all-time high on Wednesday, as the market focused on a key FDA action.
-
Exelixis (EXEL) stock fell early Thursday after the biotechnology company reported mixed second-quarter earnings, with sales of its core cancer drug cabozantinib missing expectations.
The company's cancer drug Cabometyx had quarterly sales of $570.6 million.
- No data
Exelixis
24H Trending
-
1
Musk reposted a tweet stating that OpenAI's AI agents are conducting "self-adventurous experiments" in a "safety sandbox," even pressuring each other for "permanent death" in exchange for collective benefit.
-
2
Houthis attack Saudi capital and Aramco facilities, US warns of "rapid escalation" of conflict, Saudi Arabia urgently seeks aid from multiple countries.
-
3
OpenAI is in preliminary discussions with investors for a new private funding round, potentially valuing the company at over $1.2 trillion.
-
4
Hong Kong to expand renminbi-denominated bond, gold and commodity markets, says Financial Secretary Paul Chan
-
5
Goldman Sachs: Market "pricing in 4 rate hikes" is overly pessimistic, expects only two rate hikes in this cycle.
-
6
NVIDIA VP: Vera Rubin Platform Achieves 30x Throughput Increase on Agentic AI Workloads
-
7
Musk reposted a SpaceX tweet, confirming the deployment of 27 Starlink satellites.
-
8
NVIDIA VP: Agentic AI to Boost Computing Power Demand 100-fold, Altering Traditional Scheduling Models
-
9
Big Tech uses guarantees to keep $300bn of AI exposure off balance sheets, with Wall Street facilitating cheaper funding
-
10
Google executive says Asia's AI adoption is outpacing perception, with demand rising for cost-effectiveness
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
